Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
Business Wire4d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
ahajournals.org19d
Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long‐Term Cardiovascular Mortality
Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid atherosclerosis and related to adverse outcome in these ...
C&EN23d
Lectin-Mediated Labeling of Alkaline Phosphatase for Enzymatic Silver Deposition-Based Electrochemical Detection of Glycoprotein Tumor Markers
Center for Advanced Analytical Science, Guangzhou Key Laboratory of Sensing Materials and Devices, Guangdong Engineering Technology Research Center for Sensing Materials and Devices, School of ...
Yahoo Finance29d
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...
Business Wire29d
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is ...